BMS And Prothena’s Expanded Deal Shows Growing Confidence In Targeting Tau

But First Clinical Benefits Yet To Be Seen

 
• By Andrew McConaghie
  
BMS
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Business Strategy

More from In Vivo